利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.054 秒)

    Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same
    3.
    发明授权
    Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same 有权
    欧氏结核杆菌血吸虫嗜血杆菌疫苗及其使用方法

    公开(公告)号：US08637047B2

    公开(公告)日：2014-01-28

    申请号：US10975702

    申请日：2004-10-28

    申请人： John Randall Swart ,  Eric Martin Vaughn ,  Karen E. Freking ,  Michael B. Roof ,  Phillip Wayne Hayes ,  Reid C. Phillips

    发明人： John Randall Swart ,  Eric Martin Vaughn ,  Karen E. Freking ,  Michael B. Roof ,  Phillip Wayne Hayes ,  Reid C. Phillips

    IPC分类号： A61K39/116 ,  A61K39/102

    CPC分类号： A61K39/102 ,  A61K39/0241 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55566

    摘要： The present invention provides a composition and an improved single dose vaccine against E. rhusiopathiae and an improved single dose vaccine against E. rhusiopathiae and H. parasuis which provides one or more of the following: 1) confers effective immunity against E. rhusiopathiae and/or H. parasuis; 2) decreases the risk of developing clinical signs of E. rhusiopathiae and/or H. parasuis infection; 3) induces an immune response against E. rhusiopathiae and/or H. parasuis; and 4) has a DOI against E. rhusiopathiae and/or H. parasuis of at least four months. The composition or E. rhusiopathiae vaccine as well as the combined E. rhusiopathiae-H. parasuis composition or vaccine each includes a bacterial component of inactivated E. rhusiopathiae bacteria and a suitable adjuvant. The combined E. rhusiopathiae-H. parasuis composition or vaccine further includes an amount of H. parasuis antigen. The vaccines can be administered to animals in any conventional manner. The amount of the dose for intramuscular administration is preferably less than 5 ml. The amount of E. rhusiopathiae and/or H. parasuis antigen in each dose should be enough to induce an immune response in the animal receiving the vaccine or composition and will preferably confer effective immunity against and decrease the risk of developing clinical signs resulting from E. rhusiopathiae and/or H. parasuis infection for a suitable duration of immunity.

    摘要翻译： 本发明提供组合物和改进的针对埃氏杆菌病的单一剂量疫苗和针对针对埃希氏杆菌和副猪嗜血杆菌的改进的单剂量疫苗，其提供以下一种或多种：1）赋予针对E.杆菌病和/ 或副猪嗜血菌 2）降低发生脑炎病毒和/或副猪嗜血杆菌感染的临床症状的风险; 3）诱导针对埃氏杆菌和/或副猪嗜血杆菌的免疫应答; 和4）具有至少四个月的针对埃氏杆菌和/或副猪嗜血杆菌的DOI。 组合物或E.杆菌病疫苗以及组合的脑炎病毒H。 副产物组合物或疫苗各自包括灭活的肠球菌属细菌的细菌组分和合适的佐剂。 合并的脑炎病毒H。 副产物组成或疫苗还包括一定量的副猪嗜血杆菌抗原。 疫苗可以以任何常规方式施用于动物。 肌内给药的剂量优选小于5ml。 每种剂量的肠球菌和/或副猪嗜血杆菌抗原的量应足以在接受疫苗或组合物的动物中诱导免疫应答，并且优选地赋予有效的免疫力并降低由E引起的临床体征的风险 rhusiopathiae和/或副猪嗜血杆菌感染，具有合适的免疫持续时间。

    Cyclopentane (ene) oic acid, 2-alkenyl derivatives as therapeutic agents
    8.
    发明授权
    Cyclopentane (ene) oic acid, 2-alkenyl derivatives as therapeutic agents 失效
    环戊烷（烯）酸，2-烯基衍生物作为治疗剂

    公开(公告)号：US06258844B1

    公开(公告)日：2001-07-10

    申请号：US09194457

    申请日：1998-11-24

    申请人： Michael E. Garst ,  Michael B. Roof ,  Ming F. Chan ,  David F. Woodward ,  Robert M. Burk ,  Todd S. Gac ,  Steven W. Andrews

    发明人： Michael E. Garst ,  Michael B. Roof ,  Ming F. Chan ,  David F. Woodward ,  Robert M. Burk ,  Todd S. Gac ,  Steven W. Andrews

    IPC分类号： A67K31215

    CPC分类号： A61K31/5575 ,  C07C405/00 ,  Y10S514/913

    摘要： The invention relates to the use of omega chain modified prostaglandins as ocular hypotensive. The derivatives used in accordance with the invention are encompassed by the following structure formula I: wherein the hatched segments represent &agr; bonds; the wavy segment represents an &agr; or &bgr; bond; dashed lines represent a double bond or a single bond; X is selected from the group consisting of —OR and N(R2); Y is=O or represents 2 hydrogen radicals, provided that Y represents 2 hydrogen radicals when X is OH; R is hydrogen or a lower alkyl radical having up to six carbon atoms; R1 is=O or hydroxy; m is 0, 2, 4 or 6, provided that m is not 4 when the wavy segment represents a &bgr; bond; n is 0, 2, 4 or 6; x and y are 0 or 1, provided that x is 1 when y is 0 and y is 1 when x is 0; or 9, 11 and/or 15 ester derivatives of said compound of formula I, e.g. a C1 to C6 alkyl ester derivative; or a pharmaceutically acceptable salt thereof. In a further aspect, the present invention relates to an ophthalmic solution comprising a therapeutically effective amount of a compound of formula (I), wherein the symbols have the above meanings, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application.

    摘要翻译： 本发明涉及使用ω-链修饰的前列腺素作为眼压降低。 根据本发明使用的衍生物包括下列结构式I：其中阴影线段代表α键; 波浪段表示α或β键; 虚线表示双键或单键; X选自-OR和N（R2）; Y为= O或表示2个氢原子，条件是当X为OH时，Y表示2个氢原子; R是氢或具有至多6个碳原子的低级烷基; R1为= O或羟基; m为0,2,4或6，条件是当波浪段代表β键时m不为4; n为0,2,4或6; x和y为0或1，条件是当y为0时x为1，当x为0时y为1; 或所述式I化合物的9,11和/或15酯衍生物，例如。 C1-C6烷基酯衍生物; 或其药学上可接受的盐。 在另一方面，本发明涉及一种眼用溶液，其包含治疗有效量的式（I）化合物，其中符号具有上述含义，与无毒的眼科可接受的液体载体混合，包装在 适用于计量应用的容器。